

Genocea Biosciences Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 08-Feb-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 11

 Phase 2 Clinical..... 12

 Discovery..... 23

[Return to Table of Contents](#)

Genocea Biosciences Inc

COMPANY OVERVIEW

Company Name	Genocea Biosciences Inc
Parent Company Name	Genocea Biosciences Inc
Website	http://www.genocea.com/
Country	US
Number of Drugs in Active Development	6
Number of Inactive Drugs	1
Number of Patents as Owner	15
Number of Patents as Third Party	0
Number of Deals	15
Key Indications	HSV-2 infection, Streptococcus pneumoniae infection, Chlamydia trachomatis infection, Cancer, Plasmodium falciparum infection, Sepsis, Chlamydia infection, Bacterial meningitis, Bacterial pneumonia, Chlamydia pneumoniae infection, Herpes simplex virus infection, Klebsiella pneumoniae infection, Moraxella catarrhalis infection, Neisseria gonorrhoeae infection, Otitis media, Pneumocystis carinii infection, Sinusitis, Staphylococcus aureus infection
Key Target-based Actions	CD4 agonist, T-cell surface glycoprotein CD8 stimulator, IL-17 agonist, Trans acting transcription protein ICP4 modulator, TLR agonist, Herpesvirus envelope glycoprotein D stimulator, Herpesvirus envelope glycoprotein G stimulator, IL-12 agonist, Trans acting transcription protein ICP4 stimulator
Key Technologies	Antigen, Biological therapeutic, Parenteral formulation unspecified, Peptide, Natural product, Liposome formulation, Glycoprotein, Intramuscular formulation, Nanoparticle

COMPANY PROFILE

SUMMARY

Genocea Biosciences was founded in 2006 based on the technology developed from University of California at Berkeley and Harvard Medical School, with the aim of commercializing key breakthroughs in vaccine discovery. Genocea utilizes its technology which enables it to rapidly identify antigens which result in the in vivo stimulation of protective CD8+ and CD4+ T cells. These targets can then be incorporated into an existing antigen delivery system to produce multivalent vaccines.

LICENSING AGREEMENTS

In April 2010, the US Naval Medical Research Center (NMRC) entered into a cooperative research and development agreement (CRADA) with Genocea Biosciences to identify antigens for the development of a malaria vaccine against Plasmodium falciparum. Genocea would apply its technology to identify novel T-cell antigens while NMRC was to share their experience and materials for developing subunit malaria vaccines. The antigen discovery was funded by US Army Medical Research and Materiel Command (USAMRMC) to Genocea. Financial terms were undisclosed.

In February 2010, Genocea Biosciences licensed an extensive patent estate related to herpes simplex virus (HSV) type 2 antigens from the University of Washington and the Fred Hutchinson Cancer Research Center. The patents complemented Genocea's novel antigens which were discovered by its unique and proprietary antigen discovery technology. Financial terms were undisclosed.

In December 2007, the company licensed 14 antigens to Chlamydia trachomatis from Harvard Medical School, discovered by Dr Darren Higgins, the scientific founder of Genocea. These antigens had previously shown promising therapeutic potential for vaccine development.

EARLY R&D

By December 2007, GENO-004 against an undisclosed target was listed on Genocea's pipeline; this was still the case in February 2009.

[Return to Table of Contents](#)



FINANCIAL

In November 2014, the company entered into a loan and security agreement with Hercules Technology Growth Capital, Inc for a term loan of up to \$27.0 million. In addition, Genoclea entered into an equity rights letter agreement with Hercules and Hercules purchased 223,463 shares of Genoclea's common stock at \$8.95 per share, which was the closing price of Genoclea's common stock as reported on The NASDAQ Global Market on November 19, 2014 and at that time, the proceeds of the initial draw of \$12.0 million would be used to repay Genoclea's existing term loan facility and to provide additional working capital for general corporate purposes and the company would draw up to an additional \$5.0 million at its option through June 30, 2015. Two further tranches of \$5.0 million each would be drawn down at Genoclea's option on or prior to December 15, 2015 subject to the achievement of certain clinical and corporate milestones.

In July 2014, the company announced an underwritten public offering of 3.4 million shares of its common stock; later that month, Genoclea decided not to pursue the underwritten public offering .

In March 2014, the company was added to the Russell 3000 and Russell 2000 Indices.

In December 2013, the company filed a registration statement for a proposed initial public offering of shares of its common stock; in February 2014, the company announced an initial public offering of 5.5 million shares of its common stock at a price of \$12 per share. At that time, underwriters were granted a 30-day option to purchase up to an additional 825,000 shares to cover any over-allotments. The shares were traded on the NASDAQ Global Market under the ticker symbol 'GNCA' and expected to close on February 10, 2014. Later that month, the company raised net proceeds of \$61.4 million in the closed offering.

In October 2012, the company raised \$30 million in series C financing. With the close of the financing round, Genoclea had raised a total of \$76 million in equity financing.

In January 2011, Genoclea raised \$35 million in series B financing.

In February 2009, the company raised \$23 million in series A financing.

R&D GRANTS

In April 2010, Genoclea Biosciences was awarded funding from the US Army Medical Research and Materiel Command (USAMRMC) to identify novel T-cell antigens for the development of a malaria vaccine against *Plasmodium falciparum*. Genoclea received \$2.7 million from USAMRMC.

The University of Pittsburgh Medical Center's Sexually Transmitted Infections Cooperative Research Center awarded Genoclea Biosciences a grant for the development of vaccines for *Chlamydia trachomatis*.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Infectious disease	5	1	6
Neoplasm	1	0	1
Respiratory disease	1	0	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	2
Discovery	4
No Development Reported	1

[Return to Table of Contents](#)

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	1	0	0	0	1
Patent - Exclusive Rights	0	0	3	0	3
Drug - Funding	4	0	0	0	4
Drug - CRADA	1	0	0	0	1
Drug - Early Research/Development	0	0	2	0	2
Drug - Development/Commercialization License	0	0	1	0	1
Drug - Manufacturing/Supply	0	0	1	0	1
Drug - Development Services	0	0	1	0	1
Technology - Delivery/Formulation	0	0	1	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Infectious disease	2	3

Trials by Phase

Phase	Ongoing	All
Phase 2	3	4
Phase 1	1	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Neoplasm	1	0	1
Neurological disease	1	0	1

[Return to Table of Contents](#)



Respiratory disease	5	0	5
Infectious disease	13	0	13
Inflammatory disease	1	0	1
Otorhinolaryngological disease	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

GEN-004

GEN-004 SNAPSHOT

Drug Name	GEN-004
Key Synonyms	
Originator Company	Genocea Biosciences Inc
Active Companies	Boston Children's Hospital;Program for Appropriate Technology in Health;Genocea Biosciences Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Streptococcus pneumoniae infection
Target-based Actions	IL-17 agonist;T-cell surface glycoprotein CD8 stimulator;CD4 agonist
Other Actions	Adjuvant;Protein subunit vaccine;Prophylactic vaccine
Technologies	Natural product;Biological therapeutic;Parenteral formulation unspecified;Antigen;Peptide
Last Change Date	18-Sep-2014

GEN-004 DEVELOPMENT PROFILE

SUMMARY

PATH, Children's Hospital Boston, in collaboration with Genocea Biosciences, are developing GEN-004 (GENO-002; GENO-4), a protein-subunit vaccine that contains three protein antigens, SP0148, SP1912, and SP2108, and targets the T helper-17 pathway, using the company's T-cell antigen discovery technology that stimulates CD4 and CD8 cells, for the potential prevention of infection caused by Streptococcus pneumoniae,. In September 2014, a phase IIa trial was initiated in the UK and at that time, interim data were expected in mid-2015. In November 2013, a phase I study of the vaccine in healthy adult subjects was initiated in the US ; in June 2014, positive top-line data were reported.

PATH and Children's Hospital Boston are also investigating a whole-cell pneumococcal vaccine .

GEN-004 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Boston Children's Hospital	Streptococcus pneumoniae infection	UK	Phase 2 Clinical	11-Sep-2014
Genocea Biosciences Inc	Streptococcus pneumoniae infection	UK	Phase 2 Clinical	11-Sep-2014
Program for Appropriate	Streptococcus pneumoniae infection	UK	Phase 2 Clinical	11-Sep-2014

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Technology in Health	Streptococcus pneumoniae infection	UK	Phase 2 Clinical	11-Sep-2014
Boston Children's Hospital	Streptococcus pneumoniae infection	US	Phase 1 Clinical	26-Nov-2013
Genocea Biosciences Inc	Streptococcus pneumoniae infection	US	Phase 1 Clinical	26-Nov-2013
Program for Appropriate Technology in Health	Streptococcus pneumoniae infection	US	Phase 1 Clinical	26-Nov-2013

GEN-004 DRUG NAMES

Names	Type
GENO-002	
GEN-004	Research Code
GENO-4	Research Code
protein subunit vaccine (antigen, Streptococcus pneumoniae), Genocea/PATH/Children's Hospital Boston	

GEN-004 CLINICAL TRIALS

Total Trials by Phase and Status


Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	1	1	1	0	0	2	2

[Return to Table of Contents](#)


GEN-004 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Active Deals
Total: 4




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Genocea Biosciences Inc	1	0	2	0	3
Boston Children's Hospital	1	0	1	0	2
Program for Appropriate Technology in Health	1	0	1	0	2
Novavax Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	2	0	2
Technology - Other Proprietary	1	0	1
Technology - Delivery/Formulation	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Genocoea Biosciences Inc	3	0	3
Boston Children's Hospital	3	0	3
University of Alabama	1	0	1
Program for Appropriate Technology in Health	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	2
Process	1
Formulation	1

GEN-003

GEN-003 SNAPSHOT

Drug Name	GEN-003
Key Synonyms	
Originator Company	Genocea Biosciences Inc
Active Companies	Genocea Biosciences Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	HSV-2 infection
Target-based Actions	T-cell surface glycoprotein CD8 stimulator;CD4 agonist;Trans acting transcription protein ICP4 modulator
Other Actions	Therapeutic vaccine;Antiviral;Immunostimulant;Ganglioside GD2 modulator;Protein subunit vaccine;Adjuvant
Technologies	Nanoparticle formulation injectable;Biological therapeutic;Parenteral formulation unspecified;Intramuscular formulation;Antigen;Glycoprotein;Liposome formulation;Peptide
Last Change Date	22-Jan-2015

GEN-003 DEVELOPMENT PROFILE

SUMMARY

Genocea Biosciences is developing GEN-003 (GENO-003; GEN-003/MM-2), a therapeutic protein subunit vaccine comprising of two recombinant T cell antigens, GB-208, a T cell antigen and internal fragment of the immediate early (IE) protein ICP4 and GB-217, a B cell antigen (glycoprotein D, or gD; gD2) proteins in combination with adjuvant Matrix-M (MM-2), using the company's T-cell antigen discovery technology (AnTigen Lead Acquisition System (ATLAS)) that stimulates CD4 and CD8 cells, for the potential intramuscular treatment of moderate-to-severe HSV-2 infection,,. In July 2014, a phase II dose optimization trial was initiated. In January 2015, patient enrollment was completed. At that time, top-line data were expected in the late second quarter of 2015 ; later that month, a rollover phase II trial was initiated . In March 2014, additional phase II studies were being planned .

GEN-003 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Genocea Biosciences Inc	HSV-2 infection	US	Phase 2 Clinical	15-Aug-2012

[Return to Table of Contents](#)



GEN-003 DRUG NAMES

Names	Type
therapeutic protein subunit vaccine (antigen, HSV-2 infection), Genocera Biosciences	
GEN-003/MM-2	
GENO-003	Research Code
GB-208 + GB-217 + Matrix-M2 (intramuscular, HSV-2 infection), Genocera Biosciences	
GEN-003	Research Code
HSV 2 therapeutic vaccine, Genocera Biosciences	

GEN-003 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
HSV-2 infection											
0	0	0	0	2	3	0	0	0	0	2	3

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	2	3	0	0	0	0	2	3

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

GEN-003 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Genocea Biosciences Inc	0	0	4	0	4
Indiana University	1	0	0	0	1
FUJIFILM Holdings Corp	1	0	0	0	1
Novavax Inc	1	0	0	0	1
University of Washington	1	0	0	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Manufacturing/Supply	1	0	1
Patent - Exclusive Rights	1	0	1
Drug - Development Services	1	0	1
Technology - Delivery/Formulation	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Genocea Biosciences Inc	3	0	3

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	2
General interest	1

[Return to Table of Contents](#)

GENO-2

GENO-2 SNAPSHOT

Drug Name	GENO-2
Key Synonyms	
Originator Company	Genocea Biosciences Inc
Active Companies	Genocea Biosciences Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	HSV-2 infection
Target-based Actions	CD4 agonist;T-cell surface glycoprotein CD8 stimulator
Other Actions	Prophylactic vaccine;Protein subunit vaccine
Technologies	Biological therapeutic;Parenteral formulation unspecified;Antigen;Peptide
Last Change Date	22-Aug-2014

GENO-2 DEVELOPMENT PROFILE

SUMMARY

Genocea Biosciences is investigating GENO-2, a protein subunit vaccine comprising adjuvant Matrix-M, using the company's T cell antigen discovery technology that stimulates CD4 and CD8 cells, for the potential prevention of HSV-2 infection,. By May 2010, preclinical animal proof-of-concept (POC) studies had been completed. In May 2012, the program was in animal validation studies. In August 2014, the drug was listed as being in preclinical development.

GENO-2 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Genocea Biosciences Inc	HSV-2 infection	US	Discovery	06-May-2010

GENO-2 DRUG NAMES

Names	Type
prophylactic protein subunit vaccine (Matrix-M, antigen, HSV-2 infection), Genocea Biosciences	
GENO-2	Research Code
HSV-2 prophylactic vaccine, Genocea Biosciences	


[Return to Table of Contents](#)



GENO-2 DEALS AND PATENTS

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Genocea Biosciences Inc	3	0	3

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	2
General interest	1

GENO-1

GENO-1 SNAPSHOT

Drug Name	GENO-1
Key Synonyms	
Originator Company	Genocea Biosciences Inc
Active Companies	Genocea Biosciences Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Chlamydia trachomatis infection
Target-based Actions	CD4 agonist;T-cell surface glycoprotein CD8 stimulator
Other Actions	Therapeutic vaccine;Protein subunit vaccine;Adjuvant;Antibacterial
Technologies	Natural product;Biological therapeutic;Parenteral formulation unspecified;Antigen
Last Change Date	22-Aug-2014

GENO-1 DEVELOPMENT PROFILE

SUMMARY

Genocea Biosciences is investigating GENO-1 (GENO-001), a protein subunit vaccine, using the company's T cell antigen discovery technology that stimulates CD4 and CD8 cells, for the potential treatment of Chlamydia trachomatis infection,. In May 2012, the vaccine was listed as being in animal validation studies. In August 2014, the vaccine was listed as being in preclinical development.

GENO-1 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Genocea Biosciences Inc	Chlamydia trachomatis infection	US	Discovery	18-Dec-2007

GENO-1 DRUG NAMES

Names	Type
GENO-001	Research Code
protein subunit vaccine (antigen, Chlamydia trachomatis infection), Genocea	
GENO-1	Research Code
Chlamydia trachomatis vaccine, Genocea Biosciences	


[Return to Table of Contents](#)



GENO-1 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Genocea Biosciences Inc	1	0	3	0	4
University of Pittsburgh	0	0	1	0	1
Harvard University	1	0	0	0	1
Novavax Inc	1	0	0	0	1
Harvard Medical School	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Early Research/Development	1	0	1
Drug - Funding	1	0	1
Patent - Exclusive Rights	1	0	1
Technology - Delivery/Formulation	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Genocea Biosciences Inc	1	0	1

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Tentative	1

GENO-5

GENO-5 SNAPSHOT

Drug Name	GENO-5
Key Synonyms	
Originator Company	Genocea Biosciences Inc
Active Companies	US Naval Medical Research Center;Genocea Biosciences Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Plasmodium falciparum infection
Target-based Actions	CD4 agonist;T-cell surface glycoprotein CD8 stimulator
Other Actions	Protein subunit vaccine;Adjuvant;Prophylactic vaccine
Technologies	Natural product;Biological therapeutic;Parenteral formulation unspecified;Antigen;Peptide
Last Change Date	25-Aug-2014

GENO-5 DEVELOPMENT PROFILE

SUMMARY

Genocea Biosciences, in collaboration with US Naval Medical Research Center (NMRC), is investigating GENO-5, a malarial protein-subunit vaccine, using the company's T cell antigen discovery technology that stimulates CD4 and CD8 cells, for the potential prevention of Plasmodium falciparum infection,. In June 2010, the vaccine was in discovery; in August 2014, this was still the case. In May 2012, the vaccine was in human screen studies.

GENO-5 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Genocea Biosciences Inc	Plasmodium falciparum infection	US	Discovery	15-Apr-2010
US Naval Medical Research Center	Plasmodium falciparum infection	US	Discovery	15-Apr-2010

GENO-5 DRUG NAMES

Names	Type
GENO-5	Research Code
protein-subunit malaria vaccine (antigen, Plasmodium falciparum infection), Genocea Biosciences/NMRC	


[Return to Table of Contents](#)



GENO-5 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Genoclea Biosciences Inc	3	0	1	0	4
US Government	0	0	2	0	2
Novavax Inc	1	0	0	0	1
Bill & Melinda Gates Foundation	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	2	0	2
Technology - Delivery/Formulation	1	0	1
Drug - CRADA	1	0	1

[Return to Table of Contents](#)

melanoma vaccine (ATLAS), Genoclea/Dana-Farber Cancer Institute

melanoma vaccine (ATLAS), Genoclea/Dana-Farber Cancer Institute SNAPSHOT

Drug Name	melanoma vaccine (ATLAS), Genoclea/Dana-Farber Cancer Institute
Key Synonyms	
Originator Company	Genoclea Biosciences Inc
Active Companies	Dana-Farber Cancer Institute Inc;Genoclea Biosciences Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	T-cell surface glycoprotein CD8 stimulator;CD4 agonist
Other Actions	Protein subunit vaccine;Therapeutic vaccine;Anticancer
Technologies	Antigen;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	09-Apr-2014

melanoma vaccine (ATLAS), Genoclea/Dana-Farber Cancer Institute DEVELOPMENT PROFILE

SUMMARY

Genoclea Bioscience in collaboration with Dana-Farber Cancer Institute, is investigating a protein subunit vaccine comprising of T cell antigens, using Genoclea's AnTigen Lead Acquisition System (ATLAS) technology that stimulates CD4 and CD8 cells, for the potential treatment of melanoma . In March 2014, development was ongoing.

melanoma vaccine (ATLAS), Genoclea/Dana-Farber Cancer Institute DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Dana-Farber Cancer Institute Inc	Cancer	US	Discovery	03-Mar-2014
Genoclea Biosciences Inc	Cancer	US	Discovery	03-Mar-2014


melanoma vaccine (ATLAS), Genoclea/Dana-Farber Cancer Institute DRUG NAMES

Names	Type
melanoma vaccine (ATLAS), Genoclea/Dana-Farber Cancer Institute	

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Genoclea Biosciences Inc	0	0	1	0	1
Harvard Medical School	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Early Research/Development	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

